Table I.
Expression and association of lncRNAs in osteosarcoma.
| Chemotherapeutic drug | lncRNA | Deregulation | Genes/proteins affected | Signaling pathway | (Refs.) |
|---|---|---|---|---|---|
| Gemcitabine | PVT1 | Up | microRNA-152 | c-MET/PI3K/AKT | (61) |
| KCNQ1OT1 | Up | DNMT1/Kcnq1 | – | (62) | |
| TUG1 | Up | – | MET/Akt | (63) | |
| CDDP | OIP5-AS1 | Up | miR-340-5p/LPAATβ | PI3K/AKT/mTOR | (64) |
| ANRIL | Not analyzed | miR-125a-5p | STAT3 | (65) | |
| HOTTIP | Up | – | Wnt/β-catenin | (69) | |
| SNHG12 | Up | miR-320a/MCL1 | – | (66) | |
| DXR | FOXC2-AS1 | Up | FOXC2/ABCB1 | – | (67) |
| methotrexate | LUCAT1 | Up | miR-200c/ABCB1 | – | (68) |
Drug resistance of osteosarcoma is one of the most important problems in the clinical treatment of osteosarcoma. Different lncRNAs play an important role in the chemoresistance of osteosarcoma, which is expected to be a breakthrough point to solve this problem. lncRNA, long non-coding RNA; miR, microRNA.